SCHEMBL6025784

SCHEMBL6025784

CC(C)C1Oc2ccc(Cl)cc2C(C(=O)NCc2ccccc2)N(CCc2c[nH]c3ccccc23)C1=O

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MC4R P32245 1/20 0.43
MAPT P10636 4/20 0.42
MEN1 O00255 3/20 0.42
KMT2A Q03164 3/20 0.42
KDM4E B2RXH2 2/20 0.42
ALDH1A1 P00352 2/20 0.42
CYP3A4 P08684 1/20 0.42
ALOX15 P16050 1/20 0.42
TSHR P16473 1/20 0.42
MAPK1 P28482 1/20 0.42
HSD17B10 Q99714 1/20 0.42
TDP1 Q9NUW8 1/20 0.42
SNCA P37840 4/20 0.42
PTGS1 P23219 1/20 0.42
NPC1 O15118 2/20 0.40
RAB9A P51151 2/20 0.40
SIRT1 Q96EB6 1/20 0.40
HTT P42858 1/20 0.40
RXFP1 Q9HBX9 1/20 0.40
ACHE P22303 2/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5560832 0.90 PTGS1 (0.43) MAPTMEN1KMT2AKDM4EALDH1A1
SCHEMBL5561024 0.89 PTGS1 (0.40) MAPTMEN1KMT2AKDM4EALDH1A1
SCHEMBL5556554 0.82 MEN1 (0.43) MAPTMEN1KMT2AKDM4EALDH1A1
SCHEMBL5556110 0.81 MTNR1A (0.44) MAPTMEN1KMT2AKDM4EALDH1A1
SCHEMBL5561897 0.81 MEN1 (0.47) MAPTMEN1KMT2ASNCAPTGS1
SCHEMBL5561127 0.80 MEN1 (0.39) MAPTMEN1KMT2AKDM4EALDH1A1
SCHEMBL5560845 0.80 MAPT (0.40) MAPT
SCHEMBL5557136 0.80 MAPT (0.41) MAPTMEN1KMT2AKDM4EALDH1A1
SCHEMBL5563229 0.78 RAB9A (0.40) MAPTMEN1KMT2AKDM4EALDH1A1
SCHEMBL5557097 0.78 ALDH1A1 (0.42) MAPTMEN1KMT2AKDM4EALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7060698-B2 Benzoxazepinone derivatives HOFFMANN-LA ROCHE INC. (US) 2006-06-13 US disclosed
US-20040235819-A1 5-alkylaminocarbonyl-substituted, e.g., 4-(1-benzyl-piperidin-4-yl)-2-isopropyl-3-oxo-2,3,4,5-tetrahydro-benzo[f][1,4]oxazepine-5-carboxylic acid tert-butylamide; gamma -secretase inhibitors for the treatment of Alzheimer's disease. HOFFMANN-LA ROCHE INC. 2004-11-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040235819-A1 5-alkylaminocarbonyl-substituted, e.g., 4-(1-benzyl-piperidin-4-yl)-2-isopropyl-3-oxo-2,3,4,5-tetrahydro-benzo[f][1,4]oxazepine-5-carboxylic acid tert-butylamide; gamma -secretase inhibitors for the treatment of Alzheimer's disease. BACE1, BACE2, PSEN1 MC4R 3054/4885MAPT 318/4885MEN1 4394/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.